The doctor–pharma nexus is as much an ethical problem as a regulatory one. Discuss.

The doctor–pharma nexus is the trading of gifts, hospitality or travel by drug companies for prescriptions. On 8 October 2026 the Supreme Court directed the Centre to set up an expert committee on statutory rules for pharma marketing [1]. This shows the nexus is both a failure of professional conscience and a gap in the law.

Ethical dimension

• Conflict of interest: incentives weaken the doctor's fiduciary duty to prescribe in the patient's interest rather than the giver's.
• Irrational prescribing: in the Dolo-650 case, the CBDT alleged that the maker spent ₹1,000 crore on freebies to doctors. The drug was a 650 mg dose that fell outside price control [3].
• Corporate ethics: the petitioners are a federation of medical representatives (FMRAI), the companies' own sales staff. Their case targets the firms' unethical marketing [1].
• Equity: brand-driven prescribing raises out-of-pocket costs and hurts the poor most. This erodes the right to health under Article 21 [3].

Regulatory dimension

• No statutory backing: UCPMP 2015 was voluntary [4]. UCPMP 2024 is still an executive code of the Department of Pharmaceuticals, not an Act of Parliament [1].
• Self-regulation: complaints first go to ethics committees inside industry associations. The harshest sanctions are recovery, corrective statements or expulsion from the association [2].
• Asymmetry: medical council regulations can cost a doctor their licence. The company that offered the benefit faces no comparable penalty [3].
• Grey zones: the code allows free samples and educational items worth under ₹1,000 [2]. This blurs the line between legitimate promotion and inducement.

Why both must be tackled together

• Law without ethics invites loopholes; ethics without law has no deterrence.
• A decade of voluntary codes did not prevent allegations like Dolo-650 [3][4]. Codes alone do not change behaviour when breaking them costs little.

The nexus lies where weak professional ethics meets weak enforcement. The SC-ordered committee should recommend a statute that:

• penalises companies as seriously as doctors;
• adds independent members to complaint panels;
• clearly defines what spending is permitted.

Ethics training in medical education should reinforce these rules. This dual approach would uphold Article 21 and advance SDG 3 on affordable, quality healthcare.